liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Biomarkers of diabetic nephropathy: A 2017 update
Linköping University, Department of Medical and Health Sciences, Division of Cardiovascular Medicine. Linköping University, Faculty of Medicine and Health Sciences. University of Athens, Greece.
University of Athens, Greece.
Henri Dunant Hospital, Greece.
University of Athens, Greece.
Show others and affiliations
2017 (English)In: Critical reviews in clinical laboratory sciences, ISSN 1040-8363, E-ISSN 1549-781X, Vol. 54, no 5, 326-342 p.Article, review/survey (Refereed) Published
Abstract [en]

Diabetic nephropathy (DN), also named diabetic kidney disease (DKD), is a devastating complication in patients with both type 1 and 2 diabetes mellitus (T1D and T2D) and its diagnosis has been traditionally based on the presence of micro-albuminuria (MA). The aim of this article is to update, through review of the relevant medical literature, the most promising biomarkers for early DKD detection. MA has historically been employed as an early marker of microvascular complications, indicating risk for advanced CKD. However, due to the inability of MA to adequately predict DKD, especially in young patients or in non-albuminuric DKD, additional biomarkers of glomerular and/or tubular injury have been proposed to uncover early renal dysfunction and structural lesions, even before MA occurs. Defining new predictive biomarkers to use alongside urinary albumin excretion (UAE) during the initial stages of DKD would provide a window of opportunity for preventive and/or therapeutic interventions to prevent or delay the onset of irreversible long-term complications and to improve outcomes by minimizing the rates of severe cardio-renal morbidity and mortality in DKD patients.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD , 2017. Vol. 54, no 5, 326-342 p.
Keyword [en]
Diabetic nephropathy; diabetic kidney disease; diabetes; biomarkers
National Category
Cardiac and Cardiovascular Systems
Identifiers
URN: urn:nbn:se:liu:diva-143113DOI: 10.1080/10408363.2017.1377682ISI: 000414146600003PubMedID: 28956668OAI: oai:DiVA.org:liu-143113DiVA: diva2:1159355
Available from: 2017-11-22 Created: 2017-11-22 Last updated: 2017-11-22

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Papadopoulou, Nektaria
By organisation
Division of Cardiovascular MedicineFaculty of Medicine and Health Sciences
In the same journal
Critical reviews in clinical laboratory sciences
Cardiac and Cardiovascular Systems

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 41 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf